drugset
drugset / Trial / NCT04249037

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

NCT04249037 ↗

Phase 4 Terminated 10 enrolled University of Colorado, Denver Gilead Sciences · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

This study plans to learn about whether starting HIV treatment very soon after diagnosis is more beneficial than waiting until entering routine clinical care after diagnosis.

Timeline

Start
2020-12-15
Primary completion
2023-07-01
Completion
2023-07-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator bictegravir Small molecule 50 mg —
Comparator emtricitabine Other / unclassified 200 mg —
Comparator tenofovir alafenamide Small molecule 25 mg —

Indications

HIV infectious disease